Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

A peptide aptamer to antagonize BCL-6 function

Oncogene volume 25, pages 2223–2233 (2006)Cite this article

Abstract

BCL-6 is a transcription factor essential for germinal centre B-cell development. The BCL-6 gene is involved in diffuse large-cell lymphoma and overexpressed in other types of non-Hodgkin's lymphoma and in high-grade breast cancer. BCL-6 is a transcriptional repressor whose N-terminal POZ domain mediates protein–protein interactions to exert its effects. Reasoning that disruption of POZ domain-mediated interactions may be an effective route to antagonizing the effects of BCL-6 in lymphoma, we screened a library for peptide aptamers that specifically bind to BCL-6 POZ and not the POZ domains of related proteins and describe here the first of these reagents, Apt48. Apt48 binds BCL-6 POZ in a manner distinct from the transcriptional corepressor SMRT, yet was found to prevent BCL-6-mediated repression of a luciferase reporter gene. Apt48 also reproduced several previously validated effects of BCL-6 inhibition. Notably, expression of the differentiation markers CD69, Blimp-1 and cyclin D2 was increased in B-cell lines when Apt48 was expressed. We also show that expression of Apt48 restores cytokine-mediated growth arrest to BCL-6 overexpressing cells. Thus, we have identified a peptide aptamer that affects a function of BCL-6 that is required to prevent differentiation of proliferating B cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Ahmad KF, Melnick A, Lax S, Bouchard D, Liu J, Kiang CL et al. (2003). Mol Cell 12: 1551–1564.

  • Ahmad K, Engel C, Prive G . (1998). Proc Natl Acad Sci USA 95: 12123–12128.

  • Bardwell V, Treisman R . (1994). Genes Dev 8: 1664–1677.

  • Baron BW, Nucifora G, McCabe N, Espinosa 3rd R, Le Beau MM, McKeithan TW . (1993). Proc Natl Acad Sci USA 90: 5262–5266.

  • Cattoretti G, Chang C, Cechova K, Zhang B, Ye B, Falini B et al. (1995). Blood 86: 45–53.

  • Chang C, Ye B, Chaganti R, Dalla-Favera R . (1996). Proc Natl Acad Sci USA 93: 6947–6952.

  • Chevallier N, Corcoran CM, Lennon C, Hyjek E, Chadburn A, Bardwell VJ et al. (2004). Blood 103: 1454–1463.

  • Colas P, Cohen B, Jessen T, Grishina I, McCoy J, Brent R . (1996). Nature 380: 548–550.

  • Crawford M, Woodman R, Ko Ferrigno P . (2003). Brief Funct Genomic Proteomic 2: 72–79.

  • Davies J, Hawe N, Kabarowski J, Huang Q, Zhu J, Brand N et al. (1999). Oncogene 18: 365–375.

  • Deltour S, Guerardel C, Leprince D . (1999). Proc Natl Acad Sci USA 96: 14831–14836.

  • Dent A, Shaffer A, Yu X, Allman D, Staudt L . (1997). Science 276: 589–592.

  • Dhordain P, Lin RJ, Quief S, Lantoine D, Kerckaert JP, Evans RM et al. (1998). Nucleic Acids Res 26: 4645–4651.

  • Dhordain P, Albagli O, Honore N, Guidez F, Lantoine D, Schmid M et al. (2000). Oncogene 19: 6240–6250.

  • Fujita N, Jaye DL, Geigerman C, Akyildiz A, Mooney MR, Boss JM et al. (2004). Cell 119: 75–86.

  • Fukuda T, Yoshida T, Okada S, Hatano M, Miki T, Ishibashi K et al. (1997). J Exp Med 186: 439–448.

  • Golemis EA, Serebriiskii I, Finley Jr RL, Kolonin MG, Gyuris J, Brent R . (1999). Current Protocols in Molecular Biology Ausubel F.M. et al., eds. 20.1.1–20.1.40.

  • Gyuris J, Golemis E, Chertkov H, Brent R . (1993). Cell 75 (4): 791–803.

  • Harris M, Chang C-C, Berton M, Danial N, Zhang J, Kuehner D et al. (1999). Mol Cell Biol 19: 7264–7275.

  • Huynh K, Bardwell V . (1998). Oncogene 17: 2473–2484.

  • Logarajah S, Hunter P, Kraman M, Steele D, Lakhani S, Bobrow L et al. (2003). Oncogene 22: 5572–5578.

  • Melnick A, Carlile G, Ahmad K, Kiang C, Corcoran C, Bardwell V et al. (2002). Mol Cell Biol 22: 1804–1818.

  • Melnick A, Ahmad K, Arai S, Polinger A, Ball H, Borden K et al. (2000). Mol Cell Biol 20: 6550–6567.

  • Muto A, Hoshino H, Madisen L, Yanai N, Obinata M, Karasuyama H et al. (1998). EMBO J 17: 5734–5743.

  • Niu H, Ye B, Dalla-Favera R . (1998). Genes Dev 12: 1953–1961.

  • Okabe S, Fukuda T, Ishibashi K, Kojima S, Okada S, Hatano M et al. (1998). Mol Cell Biol 18: 4235–4244.

  • Onizuka T, Moriyama M, Yamochi T, Kuroda T, Kazama A, Kanazawa N et al. (1995). Blood 86: 28–37.

  • Polo JM, Dell'Oso T, Ranuncolo SM, Cerchietti L, Beck D, Da Silva GF et al. (2004). Nat Med 10 (12): 1329–1335.

  • Reljic R, Wagner SD, Peakman LJ, Fearon DT . (2000). J Exp Med 192 (12): 1841–1848.

  • Rose MD, Winston F, Hieter P (eds). (1990). Methods in Yeast Genetics: a Lab course manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor: New York.

    Google Scholar 

  • Sambrook J, Russell DW . (2001). Molecular Cloning, a Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor: New York.

    Google Scholar 

  • Shaffer A, Yu X, He Y, Boldrick J, Chan E, Staudt L . (2000). Immunity 13: 199–212.

  • Turner CA, Mack DH, Davis MM . (1994). Cell 77: 297–306.

  • Ye B, Cattoretti G, Shen Q, Zhang J, Hawe N, Waard RD et al. (1997). Nat Genet 16: 161–170.

  • Ye B, Rao P, Chaganti R, Dalla-Favera R . (1993). Cancer Res 53: 2732–2735.

Download references

Acknowledgements

We thank Dr Yusuke Murakami (Wellcome Trust Immunology Unit, Cambridge) for help with cell culture conditions, and Sue Penryn-Lowe (MRC Cancer Cell Unit, Hutchison/MRC Research Centre) for her help both with cell counting and with microscopy and imaging. This work was funded by a grant from the Development Committee of Cancer Research UK (to SDW). Work in the PKF lab is funded by a Grant-in-Aid from the Medical Research Council to the Cancer Cell Unit. SAT acknowledges the receipt of an MRC Studentship.

Author information

Authors and Affiliations

  1. MRC Cancer Cell Unit, Hutchison/MRC Research Centre, Cambridge, UK

    A Chattopadhyay, S A Tate & P Ko Ferrigno

  2. University of Cambridge/Cancer Research UK Department of Oncology, Hutchison/MRC Research Centre, Cambridge, UK

    S A Tate & P Ko Ferrigno

  3. Department of Haematology, Division of Investigative Sciences, Imperial College London, Hammersmith Hospital, London, UK

    A Chattopadhyay, R W Beswick & S D Wagner

Authors
  1. A Chattopadhyay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S A Tate
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R W Beswick
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S D Wagner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Ko Ferrigno
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to S D Wagner or P Ko Ferrigno.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chattopadhyay, A., Tate, S., Beswick, R. et al. A peptide aptamer to antagonize BCL-6 function. Oncogene 25, 2223–2233 (2006). https://doi.org/10.1038/sj.onc.1209252

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209252

Keywords

This article is cited by

Search

Advanced search

Quick links